New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Development services for gene and cell therapies is planned to begin first in 2025
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Subscribe To Our Newsletter & Stay Updated
